0001225208-24-003056.txt : 20240227
0001225208-24-003056.hdr.sgml : 20240227
20240227134743
ACCESSION NUMBER: 0001225208-24-003056
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240223
FILED AS OF DATE: 20240227
DATE AS OF CHANGE: 20240227
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: McDermott Michael
CENTRAL INDEX KEY: 0001902464
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-03619
FILM NUMBER: 24684959
MAIL ADDRESS:
STREET 1: C/O PFIZER INC. CORPORATE SECRETARY
STREET 2: 235 EAST 42ND STREET
CITY: 235 EAST 42ND STREET
STATE: NY
ZIP: 10017
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PFIZER INC
CENTRAL INDEX KEY: 0000078003
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 135315170
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 66 HUDSON BOULEVARD EAST
CITY: NEW YORK
STATE: NY
ZIP: 10001-2192
BUSINESS PHONE: 2127332323
MAIL ADDRESS:
STREET 1: 66 HUDSON BOULEVARD EAST
CITY: NEW YORK
STATE: NY
ZIP: 10001-2192
FORMER COMPANY:
FORMER CONFORMED NAME: PFIZER CHARLES & CO INC
DATE OF NAME CHANGE: 19710908
4
1
doc4.xml
X0508
4
2024-02-23
0000078003
PFIZER INC
PFE
0001902464
McDermott Michael
66 HUDSON BOULEVARD EAST
ATTN: CORPORATE SECRETARY
NEW YORK
NY
10001-2192
1
Executive Vice President
0
Common Stock
2024-02-23
4
M
0
12412.0000
27.3400
A
95408.0000
D
Common Stock
2024-02-23
4
F
0
859.0000
27.7600
D
94549.0000
D
Common Stock
2024-02-23
4
F
0
10031.0000
27.3700
D
84518.0000
D
Common Stock
2024-02-25
4
F
0
2992.0000
27.7600
D
81526.0000
D
Common Stock
2024-02-26
4
F
0
6063.0000
27.1800
D
75463.0000
D
Stock Appreciation Rights
27.3400
2024-02-23
4
M
0
12412.0000
0.0000
D
2024-02-23
2024-02-23
Common Stock
12412.0000
0.0000
D
The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.
The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the vesting of restricted stock units (including dividend equivalents thereon).
Price is the closing price of Pfizer common stock on February 23, 2024.
The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.
Susan E. Grant, by power of atty., for Michael McDermott
2024-02-27